Gregory Gene Freitag - 01 Jun 2023 Form 4 Insider Report for Axogen, Inc. (AXGN)

Role: Director
Signature: /s/Gregory Freitag
Issuer symbol: AXGN
Transactions as of: 01 Jun 2023
Net transactions value: -$365,780
Form type: 4
Filing time: 05 Jun 2023, 18:47:34 UTC
Previous filing: 18 Jul 2024
Next filing: 17 Jul 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AXGN	Common Stock	Sale	$108,125	-12,500	-3.8%	$8.65	319,615	01 Jun 2023	Direct	F1
transaction	AXGN	Common Stock	Sale	$257,655	-29,480	-9.2%	$8.74	290,135	01 Jun 2023	Direct	F2
transaction	AXGN	Common Stock	Options Exercise	$0	+6,459	+2.2%	$0.000000	296,594	01 Jun 2023	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AXGN	Restricted Stock Units	Options Exercise	$0	-6,459	-100%	$0.000000^*	0	01 Jun 2023	Common Stock	6,459		Direct	F4, F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $8.57 to $8.75 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2	The reported price in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from $8.66 to $8.83 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F3	This reflects the number of restricted stock units that vested on June 1, 2023.
F4	Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
F5	Annual equity grant for service as Director on the Axogen, Inc. Board of Directors. The number of shares pursuant to the equity grant is based on a $120,000 valuation as of the grant date and vests on June 1, 2023, one year from the anniversary of the grant date.